Delving into the Latest Updates on SSS50 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

SSS50

Target-

Action-

Mechanism-

Therapeutic Areas

Skin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication

Androgenetic AlopeciaEndometriosis

Inactive Indication-

Originator Organization

Shenyang Sunshine Pharmaceuticals Co., Ltd.

Active Organization

Shenyang Sunshine Pharmaceuticals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估SSS50在中国健康受试者中的安全性和耐受性。次要目的：评估SSS50单次给药后在中国健康受试者中的药代动力学（PK）特征；评估SSS50单次给药后在中国健康受试者中的免疫原性。探索性目的：评估SSS50在中国健康受试者中对血清催乳素（PRL）水平的影响；评估SSS50对其他性激素水平的影响。

[Translation]

Primary Objectives: To evaluate the safety and tolerability of SSS50 in healthy Chinese subjects. Secondary Objectives: To evaluate the pharmacokinetic (PK) characteristics of SSS50 in healthy Chinese subjects after a single dose; To evaluate the immunogenicity of SSS50 in healthy Chinese subjects after a single dose. Exploratory Objectives: To evaluate the effects of SSS50 on serum prolactin (PRL) levels in healthy Chinese subjects; To evaluate the effects of SSS50 on levels of other sex hormones.

Start Date24 Oct 2025

Sponsor / Collaborator

Shenyang Sunshine Pharmaceuticals Co., Ltd.

100 Clinical Results associated with SSS50

Login to view more data

100 Translational Medicine associated with SSS50

Login to view more data

100 Patents (Medical) associated with SSS50

Login to view more data

100 Deals associated with SSS50

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Androgenetic Alopecia	Phase 1	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	24 Oct 2025
Endometriosis	IND Approval	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	09 Feb 2026